Cedar Mill Business News
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
P&G 2010 Annual Report
Touching & Improving Lives 2010 ANNUAL REPORT Net Sales Contents ($ billions) Letter to Shareholders 1 10 $78.9 Leadership Brands 7 Touching & Improving Lives 11 09 $76.7 More Consumers 12 08 $79.3 More Parts of the World 16 07 $72.4 More Completely 20 06 $64.4 P&G Innovations 24 Making a Difference 26 Financial Contents 27 Global Leadership Council 75 Operating Cash Flow Board of Directors 75 ($ billions) Financial Summary 76 Company and Shareholder Information 78 10 $16.1 09 $14.9 08 $15.0 07 $13.4 06 $11.4 Diluted Net Earnings (per common share) 10 $4.11 09 $4.26 08 $3.64 07 $3.04 06 $2.64 2010 Net Sales By business segment By geographic region By market maturity (% of total business segments) 15% 34% Beauty & Grooming 9% North America 34% Developed Health and Well-Being 42% Western Europe 48% Developing Household Care 13% Central & Eastern Europe, 66% Middle East & Africa 18% These results exclude net sales in Corporate. 21% Latin America Asia Financial Highlights (unaudited) Amounts in millions, except per share amounts 2010 2009 2008 2007 2006 Net Sales $78,938 $76,694 $79,257 $72,441 $64,416 Operating Income 16,021 15,374 15,979 14,485 12,551 Net Earnings 12,736 13,436 12,075 10,340 8,684 Net Earnings Margin from Continuing Operations 13.9% 13.9% 14.2% 13.3% 12.7% Diluted Net Earnings per Common Share from Continuing Operations $ 3.53 $ 3.39 $ 3.40 $ 2.84 $ 2.49 Diluted Net Earnings Per Common Share 4.11 4.26 3.64 3.04 2.64 Dividends Per Common Share 1.80 1.64 1.45 1.28 1.15 Dear Shareholders, P&G’s Purpose–to touch and improve lives, now and for generations to come–is inspiring and pervasive. -
Procter & Gamble Co (Pg)
PROCTER & GAMBLE CO (PG) 10-K Annual report pursuant to section 13 and 15(d) Filed on 08/08/2012 Filed Period 06/30/2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-434 THE PROCTER & GAMBLE COMPANY One Procter & Gamble Plaza, Cincinnati, Ohio 45202 Telephone (513) 983-1100 IRS Employer Identification No. 31-0411980 State of Incorporation: Ohio Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, without Par Value New York Stock Exchange, NYSE Euronext-Paris Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes o No þ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. -
Sustainability Report Contents Introduction 2020 Goals Progress P&G Profile Environmental Sustainability Social Responsibility GRI Index 2 of 75
Contents Introduction 2020 Goals Progress P&G Profile Environmental Sustainability Social Responsibility GRI Index 1 of 75 2015 Sustainability Report Contents Introduction 2020 Goals Progress P&G Profile Environmental Sustainability Social Responsibility GRI Index 2 of 75 Environmental and social responsibility are part of everyone’s job at P&G. They are integrated into our daily work and business operations. DAVID S. TAYLOR President and Chief Executive Officer NOTE TO PDF USER This PDF utilizes interactive elements. Click on contents and hyperlinks for easy navigation. ABOUT OUR 17TH ANNUAL SUSTAINABILITY REPORT This is the 17th Sustainability Report for Procter & Gamble’s worldwide operations. Data in this report cover the period from July 1, 2014, through June 30, 2015. Financial information is given in U.S. dollars. This report was prepared using the Global Reporting Initiative’s (GRI’s) G3 Reporting Guidelines. The mission of the GRI is to promote international harmonization in the reporting of relevant and credible corporate economic, environmental and social performance information to enhance responsible decision making. The GRI has not verified the contents of this report, nor does it take a position on the reliability of information reported herein. For further information about the GRI, For the latest P&G news, in-depth information on P&G’s brands, and please visit: www.globalreporting.org shareholder and career information, please visit: www.pg.com Contents Contents Introduction 2020 Goals Progress P&G Profile Environmental -
P&G 2016 Annual Report
P&G 2016 Annual Report FINANCIAL HIGHLIGHTS (UNAUDITED) NET SALES ($ BILLIONS) Amounts in billions, except per share amounts 2016 $65.3 2015 $70.7 2016 2015 2014 2013 2012 2014 $74.4 Net sales $65.3 $70.7 $74.4 $73.9 $73.1 2013 $73.9 2012 $73.1 Operating income 11.0 13.9 13.1 12.5 13.4 OPERATING CASH FLOW ($ BILLIONS) 2016 $15.4 Net earnings attributable 7.0 11.6 11.3 10.8 to Procter & Gamble 10.5 2015 $14.6 2014 $14.0 Net earnings margin from 2013 $14.9 % 11.7% 14.3% 14.0% 12.1% continuing operations 15.4 2012 $13.3 Diluted net earnings per common share from $ $2.84 $3.63 $3.50 $2.97 DILUTED NET EARNINGS (PER COMMON SHARE) continuing operations(1) 3.49 2016 $3.69 Diluted net earnings per 2.44 4.01 3.86 3.66 2015 $2.44 common share(1) 3.69 2014 $4.01 2013 $3.86 Dividends per $ $2.59 $2.45 $2.29 $2.14 common share 2.66 2012 $3.66 2016 NET SALES BY BUSINESS SEGMENT(2) 2016 NET SALES BY MARKET MATURITY Grooming 11% Baby, Feminine 28% and Family Care Health Care 11% Developing 35% 65% Developed Markets Markets Fabric and 18% Beauty Home Care 32% 2016 NET SALES BY GEOGRAPHIC REGION Europe 23% North America Greater China 44% 8% Latin America Asia Pacific India, % Middle East % 8 & Africa (IMEA) 9 8% (1) Diluted net earnings per common share are calculated based on net earnings attributable to Procter & Gamble. -
PG 10-K 6/30/2014 Section 1: 10-K (10-K)
PG 10-K 6/30/2014 Section 1: 10-K (10-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-434 THE PROCTER & GAMBLE COMPANY One Procter & Gamble Plaza, Cincinnati, Ohio 45202 Telephone (513) 983-1100 IRS Employer Identification No. 31-0411980 State of Incorporation: Ohio Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, without Par Value New York Stock Exchange, NYSE Euronext-Paris Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes o No þ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). -
MEDICINE Bufall 2019 • Volume 104Et • Number 2 In
MEDICINE BuFall 2019 • Volume 104et • Number 2 in A Bold New Vision on BLOOD RESEARCH #1 in Maryland and TOP 10 in the nation for Ear, Nose and Throat Pictured left to right: Nidhi Gupta, MD; John F. Biedlingmaier, MD; Rodney J. Taylor, MD; Kyle Monroe Hatten, MD; David J. Eisenman, MD; Kalpesh Tarun Vakharia, MD; Kevin D. Pereira, MD; Jeffrey S. Wolf, MD, FACS; Amal Isaiah, MD, PhD; Elizabeth Anne Guardiani, MD Not pictured above: The Otorhinolaryngology – Head & Neck Surgery program at University of Maryland Medical Center leads in advanced Ronna P. Hertzano, MD, PhD care. The department provides expertise in conditions that span pediatric disorders, voice and swallowing difficulties, ear disease and hearing loss, sinus and allergic disease, plastic and reconstructive surgery and head and neck neoplasms. The team continually improves surgical care for Andrea Michelle Hebert, MD head and neck tumors by increasingly employing transoral robotic surgery (TORS) and the endoscopic endonasal approach (EEA). These minimally invasive approaches result in less morbidity, easier recoveries and better cosmesis for patients. From innovative research to better understand the molecular basis of congenital and acquired hearing loss, to studying the ZSCAN4 gene in hopes of targeting cancer cells and advance regenerative medicine on a larger scale, the Otorhinolaryngology – Head & Neck Surgery program is pioneering advancements in the field. Learn more at umm.edu/ent Visit our Physician Video Channel at physicians.umm.edu Affiliated with the University of Maryland School of Medicine Bulletin Editorial Board MEDICINE Harry C. Knipp, ’76 Chairman Gary D. Plotnick, ’66 Vice Chairman John Allen, ’14 Frank M. -
Summit Partners to Acquire MDVIP
Source: Summit Partners May 02, 2014 08:33 ET Summit Partners to Acquire MDVIP National Leader in Personalized Preventive Healthcare Continues Rapid Growth BOSTON, MA--(Marketwired - May 2, 2014) - Growth equity investor Summit Partners today announced that it has entered into an agreement to acquire MDVIP from The Procter & Gamble Company (NYSE: PG). The agreement is expected to close shortly subject to standard regulatory approvals. Additional terms of the investment are not being disclosed. Founded in 2000, MDVIP is the nation's largest national network of physicians and patients in personalized preventive healthcare. The company serves more than 700 MDVIP-affiliated primary care physicians with more than 200,000 patients nationally. MDVIP offers physicians and members an alternative to the traditional primary healthcare deliver model by enabling members to have an enhanced relationship with their primary care physician. MDVIP's approach to primary care places the emphasis on "wellness" care, not just "sick" care. Summit Partners originally invested in MDVIP in 2004 and sold the company to P&G in 2009. Patient membership in MDVIP practices has nearly doubled in the past four years and expanded across the United States. P&G said the sale of MDVIP is another step in its strategy to focus the company's portfolio on core businesses where P&G can create the most value for consumers and shareowners. The transaction creates value for P&G shareowners, and P&G is confident that Summit Partners will provide strong leadership as an investor to support the needs and advance the goals of the MDVIP national network. -
Equity Research Department
January 20, 2011 Equity Research Procter & Gamble Co. PG: Initiated Coverage With Outperform Rating, $70-73 Valuation Outperform D&E Opportunities Should Drive Top-Line, Op Mgn, And EPS Growth • Summary: We have initiated coverage of PG with an Outperform rating on the Sector: Household and Personal Care shares and a $70-73 valuation range. Our rating within our Market Weight Products Household and Personal Care sector rating is based on (1) P&G's industry- Market Weight leading research and development (R&D) investments, (2) penetration acceleration in developing and emerging (D&E) markets (i.e., more relative runway versus competitors), and (3) leveraging of both scale and financial Initiation of Coverage strength to increase earnings. Near-term gross margin will likely be restrained by rising input costs. Long-term gross or operating margin expansion will likely 2010A 2011E 2012E be driven by ongoing cost-saving initiatives, improving business and product EPS Curr. Prior Curr. Prior mix, and leveraging of distribution expansion. P&G's portfolio provides a Q1 (Sep.) $0.97 $1.02 A NC$1.13NE competitive advantage with (1) broad exposure to fast-growing categories, Q2 (Dec.) 1.10 1.10 NE 1.20 NE (2) strong margin from scale in market-leading brands, and (3) efficiency Q3 (Mar.) 0.89 1.00 NE 1.11 NE entering D&E markets. P&G will likely continue to make small to midsize Q4 (June) 0.71 0.86 NE 0.95 NE accretive acquisitions. Current valuations on our 2012 estimates are 31% and FY $3.67 $3.98 NE $4.39 NE CY $3.72 $4.19 $4.61 27% below and above the low end of historical P/E and enterprise value (EV)-to- FY P/E 17.8x 16.4x 14.9x EBITDA ranges. -
Addendum to the Keystone 65 Preferred HMO Provider/Pharmacy Directory 2017
Addendum to the Keystone 65 Preferred HMO Provider/Pharmacy Directory 2017 Changes as of February 2017 For the most up-to-date list of Keystone 65 Preferred HMO contracted providers and pharmacies, please visit www.ibxmedicare.com. You may also contact our Member Help Team at 1-800-645-3965 (TTY/TDD: 711) for assistance with choosing a provider or pharmacy. Representatives are available 7 days a week, from 8 a.m. to 8 p.m. However, please be aware that on weekends and holidays from February 15 to September 30, your call may be sent to voicemail. The pharmacy network, and/or provider network may change at any time. You will receive notice when necessary. Keystone 65 offers HMO plans with a Medicare contract. Enrollment in Keystone 65 Medicare Advantage plans depends on contract renewal. KS7911 (3/17) THE FOLLOWING PROVIDERS AND PHARMACIES HAVE JOINED THE KEYSTONE 65 PREFERRED HMO NETWORK. BERKS 2600 Paper Mill Road Raguckas, Christina M., HOME INFUSION CERTIFIED Wyomissing, PA 19610 DO PHARMACIES ANESTHESIOLOGY REGISTERED (610) 844-9150 NURSE ST JOSEPH MEDICAL HEALTHCARE SURGICAL INSTITUTE Leblanc, Leanne L., MD PRACTITIONER GROUP ST EVOLUTION, LLC P OF READING Singer, Gregory M., MD LAWRENCE MEDICAL 207 East Bellevue 003293102 RHPN INTERNAL MED ASSOCIATES 002996179 Avenue 2752 Century Boulevard 002817761 003379135 2600 Paper Mill Road Reading, PA 19605 Wyomissing, PA 19610 950A N Wyomissing 3970 Perkiomen Wyomissing, PA 19610 (610) 921-9700 (610) 372-8031 Boulevard Avenue, Suite 102 Wyomissing, PA 19610 (484) 220-0051 Drew, David M., -
Download the Complete P&G 2011 Annual Report
2011 ANNUAL REPORT Innovating for Everyday Life Contents Letter to Shareholders................................. 1 Crest 3D White ......................................20 Financial Contents ....................................29 Leadership Brands .......................................9 Gain Dishwashing Liquid ........................22 Global Leadership Council .........................75 Innovating for Everyday Life ......................14 Head & Shoulders ..................................24 Board of Directors .....................................75 Gillette Guard ........................................ 16 Old Spice ...............................................26 Financial Summary ....................................76 Brazil ...................................................... 18 Disaster Relief ...........................................28 Company and Shareholder Information.....78 Net Sales ($ billions) Operating Cash Flow ($ billions) Diluted Net Earnings (per common share) 11 $82.6 11 $13.2 11 $3.93 10 $78.9 10 $16.1 10 $4.11 09 $76.7 09 $14.9 09 $4.26 08 $79.3 08 $15.0 08 $3.64 07 $72.4 07 $13.4 07 $3.04 2011 Net Sales By business segment By geographic region By market maturity 16% 19% 24% Beauty North America Developed Grooming 9% Western Europe Developing 9% Health Care 41% Central & Eastern Europe, 35% 65% Middle East & Africa Snacks & Pet Care 14% 30% Latin America 14% Fabric Care & Home Care Asia 4% Baby Care & Family Care 20% Financial Highlights (unaudited) Amounts in millions, except per share amounts 2011 2010 2009 2008 2007 Net Sales $82,559 $78,938 $76,694 $79,257 $72,441 Operating Income 15,818 16,021 15,374 15,979 14,485 Net Earnings 11,797 12,736 13,436 12,075 10,340 Net Earnings Margin from Continuing Operations 14.3% 13.9% 13.9% 14.2% 13.3% Diluted Net Earnings per Common Share from Continuing Operations $3.93 $3.53 $3.39 $3.40 $2.84 Diluted Net Earnings Per Common Share 3.93 4.11 4.26 3.64 3.04 Dividends Per Common Share 1.97 1.80 1.64 1.45 1.28 Robert A. -
The Procter & Gamble Company
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2010 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-434 THE PROCTER & GAMBLE COMPANY (Exact name of registrant as specified in its charter) Ohio 31-0411980 (State of Incorporation) (I.R.S. Employer Identification Number) One Procter & Gamble Plaza, Cincinnati, Ohio 45202 (Address of principal executive offices) (Zip Code) (513) 983-1100 (Registrant’s telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act). -
2014 Sustainability Report 2 of 68
1 of 68 2014 Sustainability Report 2 of 68 At P&G, sustainability is part of NOTE TO PDF USER This PDF utilizes interactive elements. Click on contents and hyperlinks everything we do. for easy navigation. - A.G. Lafley, P&G President, CEO and Chairman of the Board ABOUT THIS PUBLICATION This is the 16th Sustainability Report for Procter & Gamble’s worldwide operations. Data in this report cover the period from July 1, 2013, through June 30, 2014. Financial information is given in U.S. dollars. This report was prepared using the Global Reporting Initiative’s (GRI) G3 Reporting Guidelines. The mission of the GRI is to promote international harmonization in the reporting of relevant and credible corporate economic, environmental and social performance information to enhance responsible decision making. The GRI has not verified the contents of this report, nor does it take a position on the reliability of information reported herein. For further information about the GRI, For the latest P&G news, in-depth information please visit: www.globalreporting.org on P&G’s brands and shareholder and career information, please visit: www.pg.com Contents 3 of 68 Contents . 3 Environmental Sustainability . 26 Social Responsibility . 43 Conservation of Resources ..............27 Social Responsibility Programs ...........44 Introduction . 4 Cold-Water Washing ................27 Comforts of Home .................44 Leadership Statement ................4 Packaging Reduction ................28 Health and Hygiene .................45 Our Goals .........................5